
Conference Coverage
Latest News

Treatment Targets, Formulations, and the Future of Testosterone

Jonathan Rosenberg, MD, reacts to FDA approval of durvalumab plus EV for MIBC

Prostate Cancer, BPH, and Testosterone Scheduling Myths

LIB-01 enters phase 2b development for erectile dysfunction

The evolving role of urology APPs: From follow-up care to clinical leadership

Shorts










Videos
Urology Times Digital Edition







Continuing Medical Education
All News

Mohit Khera, MD, MBA, MPH, discusses preliminary research on radiofrequency therapy as a potential treatment for vasculogenic erectile dysfunction.

Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.

Faculty weigh the new class-wide blood pressure warning and why dropping the age-related limitation treats low testosterone as a syndrome, not aging.

Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.

Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.

The phase 1/2 ARGATE-001 trial will assess the safety, tolerability, and preliminary efficacy of EIK1006 in patients with metastatic androgen pathway modulation-resistant prostate cancer.

Expert urologists argue that testosterone is an underused biomarker of men’s health, and review how TRAVERSE resolved longstanding cardiovascular safety concerns.

Moderators in 4 forums reviewed ARANOTE, ARACOG, and ARASEC data and discussed what differentiates doublet options in mCSPC.

Muhammed A. Moukhtar Hammad, MBBCh, MSc, discusses real-world trends in baseline erectile dysfunction treatment across AUA sections before minimally invasive BPH procedures.

CG Oncology plans to submit a second biologics license application to the FDA for cretostimogene in BCG-unresponsive NMIBC by the end of March 2027

FDA expert panel members review how TRAVERSE and new evidence prompted testosterone label revisions, and what they mean for treating deficiency.

Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.

The approval is supported by data from the phase 3 VOLGA trial.

Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.

The recommendation is backed by data from the phase 3 LITESPARK-011 trial.






































